xSPECT-based Myocardial Perfusion Scintigraphy: Consistency of Functional Values and Feasibility of Myocardial Uptake Quantitation in Patients With Suspected Coronary Artery Disease
NCT ID: NCT04583787
Last Updated: 2024-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
52 participants
INTERVENTIONAL
2021-12-07
2024-05-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
NCT06030596
Breath-hold Cardiac Hybrid SPECT/CCTA
NCT02469051
Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging
NCT00976053
Determination of Coronary Flow Reserve by Dynamic Myocardial Perfusion Scintigraphy
NCT03326167
Dynamic CT Myocardial Perfusion Imaging
NCT02593838
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with suspected CAD
99mTc-sestamibi myocardial perfusion SPECT
82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
82Rb-Chloride myocardial perfusion PET with CCTA
stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
99mTc-sestamibi myocardial perfusion SPECT
82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
82Rb-Chloride myocardial perfusion PET with CCTA
stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suspected coronary artery disease based on clinical symptoms
* Informed Consent as documented by signature
Exclusion Criteria
* Allergy against adenosine
* Allergy against iodinated contrast medium
* Recent myocardial infarction (\<1 month)
* Previous history of coronary revascularization
* Severe asthma
* Thyroid hyperfunction
* atrioventricular block (AV) Block \> I grade
* Arrhythmic cardiopathy
* Weight \>101 Kg.
* Acute or chronic renal impairment defined as Serum-Creatinine: above 1.5x upper limit of normal (ULN) and/or glomerular filtration rate (GFR) \< 30 ml/min
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
* Participation in another study with investigational drug within the 30 days preceding and during the present study,
* Enrolment of the investigator, his/her family members, employees and other dependent persons,
* Claustrophobia
* Intake of caffeine \<24 Hours before the first day of examination
* Enrolment into another study using ionizing radiation within the previous 12 months.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Siemens Corporation, Corporate Technology
INDUSTRY
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Federico Caobelli, Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Clinic of Radiology & Nuclear Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinic of Radiology & Nuclear Medicine, University Hospital of Basel
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-02090, qu20Caobelli
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.